ReviewCancers2017
Androgen Receptor Signaling in Salivary Gland Cancer.
Review in Cancers, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 96 citations in OpenAlex.
- Elraglusib, a Glycogen Synthase Kinase 3β Inhibitor, plus Chemotherapy with or without Immunotherapy in Patients with Recurrent, Metastatic Salivary Gland Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Abiraterone Acetate in Patients With Castration-Resistant, Androgen Receptor-Expressing Salivary Gland Cancer: A Phase II Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021Trial
- Metabolomic Insights Into Saliva as a Non-Invasive Surrogate for Serum to Enable Community-Based Biomarker Investigation.The Prostate · 2026Article
- Brief Report: Androgen Receptor Expression Is Associated With Male Predominance in Thymic Neuroendocrine Neoplasms.JTO clinical and research reports · 2026Article
- SEER-based survival nomogram for salivary acinar cell carcinoma using clinical and surgical factors.Medicine · 2026Article
- A Clinical and Pathological Analysis of Seven Cases of Salivary Gland Ductal Carcinoma.Cureus · 2026Article
- Testosterone and Androgen Receptor in Cancers with Significant Sex Dimorphism in Incidence Rates and Survival.Cancers · 2025Review
- Epithelial-Immune Cell Crosstalk in Salivary Gland Tumors: Implications for Tumor Progression and Diagnostic Assessment.International journal of molecular sciences · 2025Article
- Advances in Targeted and Systemic Therapy for Salivary Gland Carcinomas: Current Options and Future Directions.Current oncology (Toronto, Ont.) · 2025Review
- Cell culture in salivary gland tumor research: molecular insights of pathogenic targets and personalized medicine.Cytotechnology · 2025Review
- [Clinical and molecular epidemiology of malignant salivary gland tumors].Laryngo- rhino- otologie · 2025Review
- Androgen receptor signalling in non-prostatic malignancies: challenges and opportunities.Nature reviews. Cancer · 2025Review
- Androgen receptor overexpression by immunohistochemistry in malignant salivary gland tumors in Tanzania.BMC cancer · 2025Article
- Article
- Article
- Rare Head and Neck Cancers and Pathological Diagnosis Challenges: A Comprehensive Literature Review.Diagnostics (Basel, Switzerland) · 2024Review
- A 22-year single institution review of 119 cases of salivary duct carcinoma.Laryngoscope investigative otolaryngology · 2024Article
- Oncocytoid Salivary Tumors: Differential Diagnosis and Utility of Newly Described Immunohistochemistry.Head and neck pathology · 2024Review
- Immunoprofiles and Oncologic Outcomes of 15 Patients with Androgen Receptor-Positive Salivary Duct Carcinoma.Cancers · 2024Article
- Molecular landscape of salivary gland malignancies. What is already known?Contemporary oncology (Poznan, Poland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
Salivary gland cancers comprise a small subset of human malignancies, and are classified into multiple subtypes that exhibit diverse histology, molecular biology and clinical presentation. Local disease is potentially curable with surgery, which may be combined with adjuvant radiotherapy. However, metastatic or unresectable tumors rarely respond to chemotherapy and carry a poorer prognosis. Recent molecular studies have shown evidence of androgen receptor signaling in several types of salivary gland cancer, mainly salivary duct carcinoma. Successful treatment with anti-androgen therapy in other androgen receptor-positive malignancies such as prostate and breast cancer has inspired researchers to investigate this treatment in salivary gland cancer as well. In this review, we describe the prevalence, biology, and therapeutic implications of androgen receptor signaling in salivary gland cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.